Literature DB >> 16218784

Product-enhanced reverse transcriptase assay for replication-competent retrovirus and lentivirus detection.

Lakshmi Sastry1, Yi Xu, Lisa Duffy, Sue Koop, Aparna Jasti, Holger Roehl, Doug Jolly, Kenneth Cornetta.   

Abstract

The product-enhanced reverse transcriptase (PERT) assay has been used to detect reverse transcriptase (RT) activity associated with retroviruses. Although the PERT assay has been proposed as a method for detection of replication-competent retrovirus (RCR) and lentivirus (RCL), it has not been rigorously compared with existing methods for RCR and RCL detection. We have assessed the PERT assay for detection of RCL and RCR that may contaminate lentiviral and retroviral vectors and compared it with published methods for RCL (p24gag ELISA/gag PCR) and RCR (S+/L-) detection. Our results suggest that the PERT assay is as sensitive as p24gag ELISA and gag PCR for detection of replication-competent HIV-1 in an RCL detection assay. Comparison of detection of replication-competent retroviruses, GALV and RD114, by extended S+/L- and PERT assays indicates that both assays can detect 1 IU of each virus. Our findings suggest that the PERT assay can be used for RCL and RCR testing of a variety of retroviral vectors regardless of the structure, sequence, and envelope of the vectors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16218784     DOI: 10.1089/hum.2005.16.1227

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  7 in total

1.  Replication-competent lentivirus analysis of clinical grade vector products.

Authors:  Kenneth Cornetta; Jing Yao; Aparna Jasti; Sue Koop; Makhaila Douglas; David Hsu; Larry A Couture; Troy Hawkins; Lisa Duffy
Journal:  Mol Ther       Date:  2010-12-21       Impact factor: 11.454

Review 2.  Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production.

Authors:  Ronald J Mandel; Corinna Burger; Richard O Snyder
Journal:  Exp Neurol       Date:  2007-08-24       Impact factor: 5.330

3.  SYBR Green I-based product-enhanced reverse transcriptase assay for quantification of retroviral PFV and detection of the divalent cation preference of PFV RT.

Authors:  Xiaofang Yi; Yan Sun; Qingmei Liu; Zhi Li; Wanhong Liu; Xiaohua He; Linjuan Zhang; Yuxin Wang
Journal:  Virol Sin       Date:  2014-10       Impact factor: 4.327

4.  Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.

Authors:  Kenneth Cornetta; Lisa Duffy; Cameron J Turtle; Michael Jensen; Stephen Forman; Gwendolyn Binder-Scholl; Terry Fry; Anne Chew; David G Maloney; Carl H June
Journal:  Mol Ther       Date:  2017-09-12       Impact factor: 11.454

5.  Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection.

Authors:  Robert E Throm; Annastasia A Ouma; Sheng Zhou; Anantharaman Chandrasekaran; Timothy Lockey; Michael Greene; Suk See De Ravin; Morvarid Moayeri; Harry L Malech; Brian P Sorrentino; John T Gray
Journal:  Blood       Date:  2009-03-13       Impact factor: 22.113

6.  Development of an equine-tropic replication-competent lentivirus assay for equine infectious anemia virus-based lentiviral vectors.

Authors:  Daniel C Farley; Richard Bannister; Marie A Leroux-Carlucci; Nerys E Evans; James E Miskin; Kyriacos A Mitrophanous
Journal:  Hum Gene Ther Methods       Date:  2012-11-02       Impact factor: 2.396

7.  Development of a replication-competent lentivirus assay for dendritic cell-targeting lentiviral vectors.

Authors:  Daniel C Farley; Laura McCloskey; Barbara A Thorne; Semih U Tareen; Christopher J Nicolai; David J Campbell; Richard Bannister; Hannah J Stewart; Laura Je Pearson; Bentley J Moyer; Scott H Robbins; Leah Zielinski; Tae Kim; Pippa A Radcliffe; Kyriacos A Mitrophanous; Wayne R Gombotz; James E Miskin; Brenna Kelley-Clarke
Journal:  Mol Ther Methods Clin Dev       Date:  2015-05-13       Impact factor: 6.698

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.